REGENERON PHARMACEUTICALS, INC. SG&A Expense 2008-2025 | REGN
What is sg&a expense?
Selling, general, and administrative expenses include all non-production costs such as marketing, corporate overhead, and management salaries.
What is REGENERON PHARMACEUTICALS, INC.'s current sg&a expense?
REGENERON PHARMACEUTICALS, INC. (REGN) annual sg&a expense for 2025 was $2.70B, a 8.61% decline from 2024. REGENERON PHARMACEUTICALS, INC. sg&a expense for the quarter ending December 31, 2025 was $775.0M.
What was REGENERON PHARMACEUTICALS, INC.'s sg&a expense in 2024?
REGENERON PHARMACEUTICALS, INC. annual sg&a expense for 2024 was $2.95B, a 12.28% increase from 2023.
What was REGENERON PHARMACEUTICALS, INC.'s sg&a expense in 2023?
REGENERON PHARMACEUTICALS, INC. annual sg&a expense for 2023 was $2.63B, a 24.36% increase from 2022.
What is REGENERON PHARMACEUTICALS, INC.'s 5-year sg&a expense CAGR?
REGENERON PHARMACEUTICALS, INC. sg&a expense grew at a compound annual growth rate (CAGR) of 14.94% from FY2020 to FY2025, going from $1.35B to $2.70B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $2.70B | -8.6% | 10-K |
| FY2024 | $2.95B | +12.3% | 10-K |
| FY2023 | $2.63B | +24.4% | 10-K |
| FY2022 | $2.12B | +15.9% | 10-K |
| FY2021 | $1.82B | +35.6% | 10-K |
| FY2020 | $1.35B | +0.3% | 10-K |
| FY2019 | $1.34B | +19.0% | 10-K |
| FY2018 | $1.13B | -14.6% | 10-K |
| FY2017 | $1.32B | +12.1% | 10-K |
| FY2016 | $1.18B | +40.4% | 10-K |
| FY2015 | $838.5M | +61.5% | 10-K |
| FY2014 | $519.3M | +49.9% | 10-K |
| FY2013 | $346.4M | +64.4% | 10-K |
| FY2012 | $210.8M | +79.7% | 10-K |
| FY2011 | $117.3M | +79.8% | 10-K |
| FY2010 | $65.2M | +23.2% | 10-K |
| FY2009 | $52.9M | +8.3% | 10-K |
| FY2008 | $48.9M | - | 10-K |